Company intelligence / Profile preview

Mablytics

San Diego or New York*, California or New York*, United Statesmablytics.com ↗

Ownership: Private
Employees: ~5
Development stage: Preclinical

Overview

Mablytics specializes in developing immunotherapies and diagnostics using a novel, proprietary target with applications in cancer research. The company leverages the Trianni Mouse® platform to discover fully human monoclonal antibodies. As of now, there are no active clinical trials listed on ClinicalTrials.gov, indicating all programs are preclinical. No published clinical results yet.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodies (mAbs)
Industry: Biotech

Partnerships

Trianni, Inc. (license agreement for the Trianni Mouse® technology)

Beyond the preview

Go deeper on Mablytics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mablytics.

Explore the full profile